Table 1.
Frequently used multidimensional patient-reported outcome measures and incorporated priority constructsa
| PROM | Full name | Population of intended use | Time period of interest | Subscales (total # of items) | Total # of items (# of priority items) | Priority construct(s) (# of priority items) | Specific items per construct (with corresponding number in PROM) |
| EORTC QLQ-C30 | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 |
Cancer-specific | Past week | Global health/Quality of life (2) Physical functioning (5) Role functioning (2) Emotional functioning (4) Cognitive functioning (2) Social functioning (2) Single items (13) |
30 (13) | Physical functioning (5) Role and social functioning (4) Perceived cognition (2) Pain (2) |
Physical functioning: vigorous activity (1); walking (2, 3); bed/chair (4); ADL (5) Role and social functioning: work (6); hobbies (7); family (26); social (27) Perceived cognition: concentration (20); memory (25) Pain: (9); interference (19) |
| EORTC QLQ-BN20 | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Brain Cancer 20 |
Brain tumor-specific | Past week | Future uncertainty (3) Visual disorder (3) Motor dysfunction (3) Communication deficit (3) Single items (7) |
20 (9) | Difficulty communicating (4) Physical functioning (2) Role and social functioning (1) Pain (1) Seizures (1) |
Difficulty communicating: speech (41, 42, 43), reading (38) Physical functioning: decline (32), weakness limbs (48) Role and social functioning: family (33) Pain: headache (34) Seizures: (39) |
| FACT-Br | Functional Assessment of Cancer Therapy - Brain |
Brain tumor-specific | Past week | Physical well being (7) Social/family well being (7) Emotional well being (6) Functional well being (7) Additional concerns (23) |
50 (24) | Physical functioning (4) Role and social functioning (10) Pain (2) Symptomatic adverse effects (1) Difficulty communicating (3) Perceived cognition (4) |
Physical functioning: meeting needs (GP3), in bed (GP7), ADL (Br14); weakness limbs (Br20) Role and social functioning: friends (GS1, GS3), family (GS2, GS4, GS5), partner (GS6), sex (GS7), work (GF1, GF2), driving (Br18); Pain: (GP4); headache (An10) Symptomatic adverse effects: (GP5) Difficulty communicating: speech (Br8, Br9); reading (Br16), writing (Br17) Perceived cognition: memory (Br3); thinking (Br13); deciding (Br11); acting (Br15) |
| SF-36 | Short Form 36 Health Survey | Generic | Past 4 weeks | Physical functioning (10) Role limitations due to physical health (4) Role limitations due to emotional problems (3) Energy/fatigue (4) Emotional well being (5) Social functioning (2) Pain (2) General health (5) |
36 (21) | Physical functioning (10) Role and social functioning (9) Pain (2) |
Physical functioning: activity (3–5, 8); stairs (6, 7); walking (9–11); ADL (12) Role and social functioning: physical interference (13–16); emotional interference (17–19); social (20, 32) Pain: (21); interference (22) |
| MDASI-BT | MD Anderson Symptom Inventory Brain Tumor |
Brain tumor-specific | Past day | Symptom severity (22) Symptom interference (6) |
28 (11) | Physical functioning (3) Role and social functioning (2) Pain (1) Perceived cognition (2) Communication difficulty (2) Seizures (1) |
Physical functioning: activity (23), walking (27), weakness limbs (14) Role and social functioning: work (25), social (26) Pain: (1) Perceived cognition: memory (7), concentration (18) Communication difficulty: understanding (15), speaking (16) Seizures: (17) |
| EORTC QLQ-C15-PAL | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 - Palliative Care |
Cancer-specific | Past week | Physical functioning (3) Emotional functioning (2) Fatigue (2) Pain (2) Single items (5) Overall quality of life (1) |
15 (5) | Physical functioning (3) Pain (2) |
Physical functioning: walk (1); bed/chair (2); ADL (3) Pain: (5), interference (12) |
| FACT-G | Functional Assessment of Cancer Therapy - General |
Cancer-specific | Past week | Physical well being (7) Social/family well being (7) Emotional well being (6) Functional well being (7) |
27 (13) | Physical functioning (2) Role and social functioning (9) Pain (1) Symptomatic adverse effects (1) |
Physical functioning: meeting needs (GP3); bed (GP7) Role and social functioning: friends (GS1, GS3), family (GS2, GS4, GS5), partner (GS6), sex (GS7), work (GF1, GF2) Pain: (GP4) Symptomatic adverse effects: (GP5) |
| QOLIE-31-P | Patient Weighted Quality of Life in Epilepsy |
Epilepsy-specific | Past week | Overall quality of life (1) Part A: feeling (5) Part B: feeling (6) Part C: activities (6) Part D: cognition (7) Part E: epilepsy and ASM (4) Part F: feeling about seizures (6) Part G: feeling overall quality of life (2) Part H: health (1) Part I: areas of importance (1) |
39 (23) | Role and social functioning (6) Perceived cognition (7) Symptomatic adverse effects (4) Seizures (6) |
Role and social functioning: social (13, 17); hobbies (14), driving (15), work (16); distress (18) Perceived cognition: reasoning (19); memory (20, 21, 24); concentrating (22, 23), distress (25) Symptomatic adverse effects: (26–28), distress (29) Seizures: worry (30–33), bother (34), distress (35) |
| SQLI | Spitzer Quality of Life Index | Cancer-specific | Past week | Single items (5) | 5 (3) | Physical functioning (1) Role and social functioning (2) |
Physical functioning: ADL/transport (1) Role and social functioning: work (2), social (4) |
a
Frequently used multidimensional PROMs in brain tumor patients as identified by Dirven et al.[3].